In addition, mutant p53 can target the VEGFR2 promoter transcriptional start site and plays a role in maintaining an open conformation at that location [46] and also served as predictive biomarkers for the response of VEGFR inhibitor in advanced sarcomas [47]. The gene discussed is TP53; the disease is sarcoma.